Search Results - mingqian+feng

4 Results Sort By:
Tumor-pH–Triggered Doxorubicin Prodrug with On-Demand Shelf-Stable Precursor
This invention introduces a small-molecule doxorubicin prodrug that remains inert in blood and rapidly activates in the mildly acidic tumor microenvironment. Featuring a shelf-stable maleimide pre-prodrug that converts on demand to the ultra-acid-labile DMA form, it enables targeted chemotherapy with improved selectivity, scalable synthesis, and reduced...
Published: 10/10/2025   |   Inventor(s): Ming An, Lan Yao, Vladyslav Nazarenko
Keywords(s): Technologies
Category(s): Campus > Binghamton University
Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma
Abstract: The National Cancer Institute seeks parties to license human monoclonal antibodies and immunoconjugates and co-develop, evaluate, and/or commercialize large-scale antibody production and hepatocellular carcinoma (HCC) xenograft mouse models. An advantage of these monoclonal antibodies as a potential therapeutic is their specificity, which...
Published: 5/14/2025   |   Inventor(s): Mitchell Ho, Mingqian Feng, Dimiter Dimitrov, Heungnam Kim, Wei Gao
Keywords(s): Antibody-drug Conjugate, chimeric antigen receptor, HCC, hepatocellular carcinoma, IMMUNOTOXINS, Liver cancer
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer
Abstract: The National Cancer Institute seeks parties interested in collaborative research to further co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers. The antibody was able to inhibit tumor growth in mouse xenograft models, and corresponding immunotoxins were able to inhibit tumor cell growth in vitro Mesothelin is...
Published: 5/14/2025   |   Inventor(s): Mitchell Ho, Ira Pastan, Dimiter Dimitrov, Zhewei Tang, Mingqian Feng, Wei Gao
Keywords(s): Epitopes, MESOTHELIN, Monoclonal Antibodies
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology
A bioadhesive, mechanically robust and injectable hydrogel for biomedical applications
[Licensing negotiation in progress] [Invitation for Expression of Interest- Deadline 30 March 2021] We are inviting expressions of interest (EoI) for commercializing “A Bioadhesive, Mechanically Robust and Injectable Hydrogel for Biomedical Applications” technology. The innovation is developed by Professor BIAN Liming, Department...
Published: 9/16/2024   |   Inventor(s): Liming BIAN, Qian Feng, Kongchang Wei, Gang Li, Sien Li
Keywords(s):  
Category(s): Chemistry & Material Science, Medical Devices